Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection Background. Gastrointestinal neuroendocrine tumors have frequent loss of DPC4/SMAD4 expression, a known tumor suppressor. The impact of SMAD4 loss on gastrointestinal neuroendocrine tumors aggressiveness or cancer-related patient outcomes is not defined. We examined the expression of SMAD4 in resected gastrointestinal neuroendocrine tumors and its impact on oncologic outcomes. Methods. Patients who underwent complete curative operative resection of gastrointestinal neuroendocrine tumors were identified retrospectively (n = 38). Immunohistochemical staining for SMAD4 expression was scored by a blinded pathologist and correlated with clinicopathologic features and oncologic outcomes.
Results. Twenty-nine percent of the gastrointestinal neuroendocrine tumors were SMAD4-negative and 71% SMAD4-positive. Median overall survival was 155 months (95% confidence interval, 102-208 months). Loss of SMAD4 was associated with both decreased median disease-free survival (28 months; 95% confidence interval, 16-40) months compared with 223 months (95% confidence interval, 3-443 months) for SMAD4-positive patients (P = .03) and decreased median disease-specific survival (SMAD4: 1 These neoplasms are uncommon, with an age-adjusted annual incidence of 2.5-4.5 per 100,000. 2, 3 They are considered generally more indolent than other epithelial malignancies; however, ongoing studies continue to define subsets with discrete differences in cancer-related outcomes. A comprehensive review of NETs within the Surveillance, Epidemiology, and End Results database found the primary tumor site to be a powerful predictor of duration of survival, suggesting distinct biologic differences by anatomic location. 4 Similarly, advances in genetic analysis of NETs offer the opportunity to characterize and stratify further these tumors into useful groupings. Prior investigations have identified a correlation between anatomic site and patterns of genetic aberration. The most consistent finding is the frequent loss of genetic material on chromosome 18 in NETs arising in the small intestine. This loss has been observed in 43-100% of small bowel NETs, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] which suggests strongly the loss of crucial tumor suppressor gene(s) in this location; mutational analyses of several putative tumor suppressor genes at 18q21-18q22, however, have failed to identify mutations. 8, 10, 15 Indeed, massive parallel exome sequencing of 48 small bowel NETs (SBNET) identified a low average mutation rate and, outside of 10% of patients having frameshift mutations in p27, no recurrently mutated genes. Interestingly, 46% of NETs demonstrated some degree of loss of copy number of SMAD4, suggesting a potential role of SMAD4 in GINET carcinogenesis. 16 Together, these data suggest that SBNET is a genetically unique subset of NET and that loss of genetic material at chromosome 18 drives clinical outcome.
SMAD4 is a well-known tumor suppressor gene recognized originally as "deleted in pancreatic carcinoma locus 4" (DPC4) and is located on human chromosome 18q21.1. 17, 18 Loss of expression of the SMAD4 protein is the most commonly observed consequence of genetic mutation. This loss of function is critical, because SMAD4 is a lynchpin within the TGF-b canonical signaling pathway. 19 Importantly, loss of SMAD4 occurs in numerous solid organ neoplasms and is associated with tumor progression and metastasis. 20, 21 Identification of molecular markers in primary NETs associated with cancer progression is clinically important. Once distant metastasis occurs, the median survival decreases from 111 to 56 months.
Furthermore, there is no effective systemic therapy currently for distant metastatic SBNET. Therefore, it is critical to increase our understanding of the biology of development of distant metastases in GINET.
Based on these preclinical data, we hypothesized that loss of SMAD4 would be associated with decreases in oncologic outcomes. The goal of our study was to evaluate cancer-specific end points in patients with primary, completely resected GINETs in relation to SMAD4 status.
METHODS
Patient data. With the approval of the Institutional Review Board (PA12-0021) of The University of Texas MD Anderson Cancer Center (MDACC), the Pathology Archive was searched for primary gastrointestinal NET (GINET) specimens with complete clinically and pathologic data from 1990-2009. All GINET diagnoses were confirmed by an MDACC pathologist. A clinically annotated tissue microarray was constructed using 52 individual tumor samples from patients diagnosed with GI-NET from formalin-fixed, paraffin-embedded archival tissue blocks and a tissue microarrayer (Beecher Instruments, Sun Prairie, WI), as described previously. 22 Patients with synchronous metastatic adenocarcinoma of another tissue origin were excluded from analysis (n = 8), leaving 44 individual tumor samples for SMAD4 immunohistochemistry in the tissue microarray; 19 of the 44 patients did not undergo curative-intent operation for treatment of GINET and were excluded from analysis. A prospectively maintained institutional tumor bank was further queried to identify additional cases of primary resected GINET; 20 additional tumors with complete clinical and pathologic data were identified and included. Therefore, a total of 38 patients were identified to have curatively resected GINETs with complete clinical and pathologic data and comprised the patient cohort.
Immunohistochemistry. SMAD4 immunohistochemical analysis was done at the clinical core laboratory at MDACC using a Lab-Vision 480-2D immunostainer (ThermoFisher, Fremont, CA). All reactions were visualized with diaminobenzidine as a chromogen. Positive and negative controls were included in each run for the antibody used. Isotype controls for antibody were used as negative controls as described previously.
23 SMAD4 antibody was purchased from Leica Biosystems Inc (#NCL-DPC4, Buffalo Grove, IL) and was diluted in 1:40. All images were captured via an Olympus DP72 camera attached to an Olympus BX51 microscope and processed via cellSens software (Olympus Scientific, Waltham, MA). SMAD4 staining, either cytoplasmic, nuclear, or both, was scored using the following criteria: 0, no staining of tumor cells; 1+ faint staining of the tumor cells as compared with surrounding normal pancreatic parenchyma; and 2+, moderate to strong tumor cell staining, of similar or greater intensity compared with surrounding normal pancreatic parenchyma. The percentage of tumor cells staining was noted as well. For statistical analysis, a SMAD4 score = 0 was considered "SMAD4-negative," whereas scores of 1+ or 2+ in greater than or equal to 10% of tumor cells were classified as "SMAD4-positive." Representative micrographs are shown in Fig 1. Statistical analysis. Patients were divided into dichotomous groups based on SMAD4 score, and the clinical oncologic outcomes data were analyzed. Categorical variables were compared using v 2 or Fisher exact test. Wilcoxon rank-sum test (t test) and the Kruskal-Wallis test (ANOVA) were used to compare the distributions of continuous variables among different groups. Overall survival (OS) and disease-specific survival (DSS) were measured from date of operation to date of death secondary to any cause or date of GINET-specific death, respectively. Disease-free survival (DFS) was measured from the date of resection to time of pathologic or radiographic evidence of recurrent or metastatic disease or date of last follow-up, if recurrence-free. Univariate Kaplan and Meier methods were used to estimate OS, DSS, and DFS. All tests were 2-sided. Cox proportional hazards regression model, in which a backward elimination process was used for variable selection with an entry and removal limit of P < .1 and P < .05, respectively, was applied to identify independent factors associated with DSS. All analyses were performed using SPSS version 23.0 (IBM Corp., Chicago, IL) and GraphPad software (La Jolla, CA).
RESULTS
Clinicopathologic patient results. A total of 45 GINETs were evaluated for SMAD4 expression by IHC. Seven specimens (16%) had insufficient tissue for evaluation and were excluded, leaving a total of 38 GINETs with complete clinical and pathologic information available for evaluation (Table I) . Thirty (79%) were of small bowel origin and 8 (21%) arose in the large bowel. Median age at diagnosis was 59 years. Sixteen patients were female. At the time of diagnosis, all patients underwent curative-intent resection (RO) of their primary disease and radiographically evident metastases (when applicable). The majority of GINETs were T3 and lymph node metastases were SMAD4 IHC. Twenty-nine percent (n = 11) of the tumors had an IHC score of 0 and were classified as SMAD4-negative. Nineteen tumors had an IHC score of 1+ and 8 had a score of 2+, for a total of 27 (71%) of tumors classified as SMAD4-positive. There was no difference in the stage distribution or lymphovascular invasion based on SMAD4 status (Table I) .
Cancer-related outcomes. Median follow-up time was 76 months (77 months for survivors) with a median overall survival of 155 months (95% confidence interval [CI], 102-208 months).
Median DFS for the entire cohort was 49 months (95% CI, 10-87 months), with a DSS of 204 months (95% CI, 123-283 months). Of the 38 patients who underwent resection with curative intent, 22 developed recurrent disease. First recurrence events included: 9 liver metastases, 5 peritoneal metastases, 2 local recurrences, and 3 simultaneous liver and local recurrences (Table I) ; 82% of patients (n = 9) with GINETs that were SMAD4-negative recurred compared to 48% of patients (n = 13) with SMAD4-positive tumors (P = .04).
A total of 20 patients died during the follow-up period; of these, 14 died of metastatic GINET and 6 died of other causes. Univariate analysis of factors associated with DSS (Table II) demonstrated that loss of SMAD4 was associated with decreased median DSS (P = .04). There were no other clinical or pathologic factors identified that were associated with DSS. Loss of SMAD4 (SMAD4-negative) was associated with a lesser DFS (43 [95% CI, months) compared with patients who expressed SMAD4 (SMAD4-positive; 223 [95% CI, 3-443] months, P = .01; Fig 2, A) . Patients with no expression of SMAD4 within the primary tumor were more likely to die a cancer-related death than those whose primary tumor retained SMAD4 expression (137 [95% CI, 81-194] vs 204 [95% CI, 143-264] months, respectively; P = .04; Fig 2,  B) ; this observation translated into a decreased overall survival (SMAD4-negative: 125 [95% CI, 51-214] months vs SMAD4-positive: 185 [95% CI, 138-232] months; P = .02; Fig 2, C) . Finally, when SMAD4 status was combined with LN status in assessing overall patient survival, patients with no lymph node metastases and retained SMAD4 expression in the primary tumor experienced significantly improved survival (Fig 2, D) . Although SMAD4 status was predictive for DFS and DSS on univariate analysis, we were unable to identify any clinical factors associated with survival by multivariate analysis.
DISCUSSION
This study identifies the loss of SMAD4 expression within the primary GINET tumor as being associated with decreased cancer-specific survival after resection. We performed immunohistochemical staining for SMAD4 expression of formalinfixed, paraffin-embedded slides of primary GINETs of 38 patients who underwent curative resection at our institution. Patients whose primary tumor exhibited retention of SMAD4 experienced improved oncologic outcomes when compared with those with loss of SMAD4 expression. SMAD4 loss was associated with a significant decrease in disease-free and GINET-specific survival. Additionally, loss of SMAD4 expression was associated with the presence of lymph node metastases within the specimen, and patients with both lymph node metastases and loss of SMAD4 within the primary tumor fared worse with an overall time to recurrence of only 28 months (Fig 2, D) .
SMAD4 is a well-described tumor suppressor gene that was identified originally as "deleted in pancreatic carcinoma locus 4" (DPC4). Point mutations or deletions that result in the loss of expression of the SMAD4 protein are the most common structural mutations observed. This loss of function is critical, because SMAD4 is critical for TGF-b canonical signaling 19 and thereby regulates cell proliferation, migration, bone development, differentiation, and apoptosis. 24 Importantly, loss of SMAD4 protein expression is observed in many cancers, including pancreas, breast, and prostate adenocarcinoma, and SMAD4 loss is often associated with tumor progression and metastasis. 20, 21, 25 Chaudhry et al 26 demonstrated the intimate relationship between NETs and TGF-b. Kidd et al 27 used KRJ-I cells derived from GINETs to show that loss of SMAD4 produced upregulation of c-myc and inhibition of the cell cycle checkpoint inhibitor, p21 waf1 resulting in cell proliferation and tumorigenesis. Together, these data implicate the loss of SMAD4 as a major contributor to tumor cell proliferation and progression of NETs.
For patients presenting with loco-regionally advanced GINET, resection of the primary tumor and draining regional lymph nodes remains the only potentially curative therapy. 28 Unfortunately, about half of these patients will recur and die of disease. Molecular markers to predict progression and/or metastasis are lacking which has spurred increasing studies of molecular characterization. A consistent finding of prior studies has been the frequent loss of large portions of genetic material on chromosome 18 in NETs arising in the small intestine, which has been observed in 43-100% of small bowel NETs. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] This consistent finding strongly suggests loss of crucial tumor suppressor gene(s) in this chromosomal location. Chromosome 18 harbors several candidate tumor suppressor genes, including deleted in colon cancer (DCC), SMAD4, and SMAD2. More detailed mutational analyses of several putative tumor suppressor genes at 18q21-18q22 has failed to identify candidate mutation loci 6, 8, 10 including massive parallel exome sequencing of 48 small intestinal NETs which identified a low general mutation rate and no recurrently mutated genes. 16 Even though direct sequencing of the SMAD4 gene from GINET tumors has not identified structural mutations, we identified loss of SMAD4 protein expression in 29% of primary tumors. This observation is consistent with previous data on exome sequencing, which demonstrated loss of SMAD4 copy number in 22/48 (46%) small bowel NETs. 16 In addition, epigenetic mechanisms, including hypermethylation 29 or micro RNA targeting, 30 could be responsible for SMAD4 protein loss. Additionally, SMAD proteins, including SMAD4, are degraded through ubiquitination which can modify the levels of SMAD4 within the cytoplasm of GINET cancer cells. 31 Regardless of the mechanism, loss of SMAD4 expression has been demonstrated repeatedly as a prognostic factor associated with tumor progression and cancerrelated death in numerous solid tumors. 25, 32, 33 These data should be evaluated in the context of their limitations. First, this was a nonrandomized, retrospective, cohort study of selected patients treated with a curative resection at a single institution. In addition, the small sample limited our ability to perform substantive multivariable analyses. The majority of patients had lymph nodepositive disease, making it difficult to assess the impact of SMAD4 in patients with lymph nodenegative disease. Although the sample size of the current investigation was relatively small, and therefore, will require validation, these results suggest that expression of SMAD4 in the primary tumor could be used as a prognostic marker. In summary, consistent with the known biology of the DPC4/SMAD4 gene, the absence of SMAD4 protein expression in the primary GINETs is negatively associated with cancer-related outcomes after curative resection.
